PAVmed Full Year 2023 Earnings: EPS Beats Expectations
PAVmed (NASDAQ:PAVM) Full Year 2023 Results
Key Financial Results
Net loss: US$66.3m (loss narrowed by 26% from FY 2022).
US$9.16 loss per share (improved from US$15.03 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
PAVmed EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.2%.
Looking ahead, revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You still need to take note of risks, for example - PAVmed has 7 warning signs (and 3 which are significant) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
